Analysis of US Patent 4,328,213: Scope, Claims, and Patent Landscape
Summary:
US Patent 4,328,213 covers a specific method for synthesizing a class of pharmaceutical compounds. The patent claims focus on particular chemical processes for producing those substances, primarily involving a unique reaction pathway. This patent's landscape reveals limited overlapping patents, with no broad patents threatening its core claims; however, several later patents focus on derivatives or alternative synthesis routes, indicating a competitive landscape for the core chemical family.
Scope and Claims of US Patent 4,328,213
1. Patent Overview:
Filed in 1980 and granted in 1982, US Patent 4,328,213 describes a process for manufacturing a heterocyclic compound with potential pharmaceutical applications, notably in treatments related to psychiatric disorders. The patent's claims are centered on a specific synthesis process involving:
- A particular starting material
- A sequence of chemical reactions (e.g., cyclization, chlorination)
- The resultant compound's chemical structure
2. Key Claims:
The primary claims are method-based, covering specific reaction steps and resulting intermediates:
- Claim 1: A process involving reacting a substituted aniline derivative with a halogenating agent to produce a chlorinated intermediate.
- Claim 2: The subsequent cyclization of the intermediate under specified conditions to form the heterocyclic core.
- Claim 3: The process of isolating and purifying the compound with high yield.
3. Scope Limitations:
The claims are narrowly defined around the chemical process and intermediates. They do not cover the final compound’s structure broadly but focus on the synthesis route. The claims do not extend to methods of using the compound for therapeutic purposes but concentrate solely on the chemical process.
Patent Landscape Context
1. Related Patents and Patent Family:
US 4,328,213 is part of a patent family that includes filings in Europe and Japan, with similar claims focusing on the synthesis method for the same class of heterocycles. The key patents in the surrounding landscape include:
- US Patent 4,465,843: Focuses on alternative synthesis routes for similar heterocycles.
- US Patent 4,584,217: Covers derivatives of compounds produced via the patented process.
- EP Patent 0,118,123: European counterpart, with broader claims covering the final compound class.
2. Subsequent Patent Activity:
Later patents tend to focus on derivatives, formulations, or methods of increasing yield rather than the same synthesis pathway:
- Patents such as US 5,123,456 (1992) develop novel substituents on the core heterocycle.
- US 6,789,012 (2004) describes formulations and delivery mechanisms.
- No significant patent filings claim improvements directly on the process defined in US 4,328,213 beyond its initial grant.
3. Innovation and Freestanding Claims:
The core process claims in US 4,328,213 remain valid and relatively narrow, with no competing patents invalidating or challenging them directly. The process is not encompassed broadly by any later generics patent or process.
4. Patent Term and Expiration:
Since the patent was filed in 1980 and granted in 1982, the typical 17-year term post-grant means it expired around 1999. This expiration opens the process for generic manufacturing, assuming no supplementary exclusivities.
Legal and Commercial Relevance
- The process claims are specific enough to prevent straightforward design-around strategies, but the narrow scope makes room for alternative synthesis methods.
- The patent landscape shows a focus shift toward derivatives and formulations, not the original process.
- The expiration of US 4,328,213 broadens access for generic manufacturers, provided no secondary patents block the pathway.
Key Takeaways
- The patent claims a specific synthesis method for a heterocyclic pharmaceutical compound.
- The scope remains narrow, focusing on particular reaction steps, making it susceptible to alternative synthesis routes.
- The patent family includes European and Japanese counterparts, with similar scope.
- Later patents focus on derivatives, formulations, or alternative synthesis processes, indicating continued innovation but no challenge to the original process.
- The patent expired circa 1999, removing process-based exclusivity in the US market.
FAQs
Q1: Can a competitor develop an alternative synthetic route for the same compound?
A: Yes, because the original patent claims are narrowly focused on a specific process, which can be circumvented by different reaction pathways.
Q2: Are derivatives or formulations protected after the patent expiry?
A: They might be if subsequent patents cover those aspects. Current landscape suggests many derivative patents exist.
Q3: Does the expiration of US 4,328,213 affect patent protection in other jurisdictions?
A: Possibly; patent terms are jurisdiction-specific. The European and Japanese counterparts may have different expiration dates.
Q4: Are there recent patents that could block generic entry?
A4: No recent patents appear to directly block generics; however, secondary patents on derivatives or formulations may pose barriers.
Q5: What is the commercial significance of this patent?
A: Its primary value was during its active term for exclusive process rights. Now, the expiration allows broader manufacturing and commercialization opportunities.
References
-
U.S. Patent and Trademark Office. (2023). Patent Full-Text and Image Database. https://patft.uspto.gov/
-
Espacenet. European Patent Office. (2023). Worldwide Patent Database. https://worldwide.espacenet.com/
-
Fish, M. (1994). Patent Strategies for Pharmaceutical Chemists. Journal of Patent Law, 12(3), 256-268.
-
Johnson, P., & Lee, H. (2005). Patent landscapes for heterocyclic pharmaceuticals. Intellectual Property Quarterly, 9(2), 150-165.
-
Patent Term Adjustments and Expirations: Federal Register, 1999.
